Back to search results

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hairy Cell Leukemia · Recurrent Hairy Cell Leukemia · Refractory Hairy Cell Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • NCI - Center for Cancer Research, Bethesda, Maryland, United States

    Contact: Study coordinator (Site Public Contact) · 800-411-1222
    Contact: Principal Investigator (Robert J. Kreitman)

  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (Seema A. Bhat)

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · 412-647-8073
    Contact: Principal Investigator (Robert L. Redner)

  • University of Virginia Cancer Center, Charlottesville, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · uvacancertrials@hscmail.mcc.virginia.edu · 434-243-6303
    Contact: Principal Investigator (Nathan L. Roberts)
Study leads

  • Seema A Bhat

    Principal Investigator

    Ohio State University Comprehensive Cancer Center LAO

View source on ClinicalTrials.gov(opens in a new tab)